Alligator Bioscience AB (publ) Interim Report January-June 2020

Alligator Bioscience AB (publ) Interim Report January-June 2020

PR Newswire

STOCKHOLM, July 13, 2020

STOCKHOLM, July 13, 2020 /PRNewswire/ --

Promising safety data for ATOR-1015

"With the new strategy announced in early April, we have put a stronger focus on Alligator's clinical development portfolio. ATOR-1015 has received a great deal of attention in connection with the positive interim data presented at AACR and ASCO, the world's two largest oncology conferences. We have also worked actively with business development and signed a research agreement with Scandion Oncology during the period, while our collaboration with Biotheus developed well and led to an additional milestone payment. The Covid-19 pandemic has been stressful but has not led to any serious delays in the clinical projects. We are now looking forward to an exciting second half of 2020 for Alligator", commented CEO Per Norlén.

Significant events April-June

Financial summary


January-June 2020

Read the complete report in the pdf below.

For further information, please contact:
Per Norlén, CEO,, +46 46-540 82 00
Andreas Johannesson, Interim CFO,, +46 46-540 82 00
Cecilia Hofvander, Director IR & Communications,, + 46 46-540 82 06

Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
Phone +46 46 540 82 00.

The information was submitted for publication, through the agency of the contact persons set out above, at 1:00 p.m. CEST on July 13, 2020.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes five lead clinical and preclinical drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit

This information was brought to you by Cision,c3153204

The following files are available for download:

Alligator Bioscience AB (publ) Interim report January-June 2020


Voltar noticias em Inglês